A phase I study to assess safety, tolerance and pharmacokinetics of oral dosing Icotinib Hydrochloride Tablets.
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2016
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Zhejiang Beta Pharma
- 21 May 2012 Status changed from recruiting to completed as reported by Chinese Clinical Trial Register.
- 15 Nov 2011 Status changed from completed to recruiting as reported by Chinese Clinical Trial Register record.
- 11 Jul 2009 New trial record